NCAB Says President’s Budget Would “Seriously Damage” Cancer Program
In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says
Biology Societies Recomend 15% Funding Increase for NIH
Clinical Trials: Data Manager Falsified NSABP Records On 3 Patients, ORI Says
Letter to The Editor: IOM Panel Urges Greater Integration Of Research
Funding Opportunities: NCI Accepts apploications For Cooperative Group Awards
Trending Stories
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” - Huiping Liu discusses mentorship, translational research on the UChicago Cancer Luminaries podcast